2024 Korea Regulatory Highlights And What’s In Store For This Year

The Pink Sheet looks at what major policies and regulations South Korean authorities prioritized in 2024 and what may be in store for this year.

A new year may have dawned, but South Korea remains engulfed in a political crisis stemming from a failed martial law attempt in early December which has led to the opposition-controlled parliament’s impeachment of both President Suk-Yeol Yoon and Acting President Duck-Soo Han in less than a month.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

07 Apr 2025

• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Korea To Revise ‘Innovative Company’ Criteria Amid Calls From Foreign Industry

01 Apr 2025

• By Jung Won Shin

South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.

Korea ‘Guide’ Program To Speed Select Innovative Products To Market

18 Feb 2025

• By Jung Won Shin

In an ongoing effort to accelerate the commercialization of select innovative drugs and medical devices, Korea’s MFDS is launching a new program for certain products that will receive regular regulatory consultations until they reach the approval stage.